Personalized treatments in lung cancer

Publish Year: 1395
نوع سند: مقاله کنفرانسی
زبان: English
View: 346

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

IPMCMED01_004

تاریخ نمایه سازی: 23 آذر 1397

Abstract:

The past decade has seen an enormous advancement in the therapy for non-small cell lung cancer, predominantly seen in adenocarcinoma.The first achievement was the knowledge that certain histologies respond better to certain drugs. This was the introduction of histology-based drugs. Then came the discovery of targetable mutations. We have many mutations in this disease, mostly still untargettable. These events have led to a personalized therapeutic approach with the delivery of drugs that target specific oncogenic pathways active in a given tumor with the intent of acquiring the best response rate. Patients benefitting here were mostly non- or never smokers. The discovery of sensitizing mutation in the epidermal growth factor receptor gene as the basis for clinical response to tyrosine kinase inhibitors led to a systematic search for other molecular targets in lung cancer. Currently, there are several molecular alterations that can be targeted by experimental drugs, such as ALK and ROS. These new discoveries would not be possible without a parallel technological evolution in diagnostic molecular pathology. Next-generation sequencing (NGS) is a technology that allows for the evaluation of multiple molecular alterations in the same sample using a small amount of tissue. Selective evaluation of targeted cancer genes, instead of whole-genome evaluation, is the approach that is best suited to enter clinical practice. In the era of immunotherapy, another lesson was learnt and that was showing a benefit in patients who did not show any of the mutations mentioned above, thus a treatment was mainly for squamous cell lung cancer and smokers.

Authors

Reza Malayeri

Firoozgar Hospital, Tehran, Iran